logo
  

H&M Group Q3 Adj. Profit After Tax Declines

H&M group (HNNMY.PK,HMRZF.PK,HEN.L) said its third quarter results were largely impacted by the company's decision to pause sales and then wind down the business in Russia. Profit after tax excluding the one-time cost for Russia was 2.15 billion Swedish kronor compared to 4.69 billion Swedish kronor, prior year. Earnings per share was 1.30 kronor compared to 2.83 kronor, last year.

Third quarter reported profit after tax declined to 531 million Swedish kronor from 4.69 billion Swedish kronor, prior year. Earnings per share was 0.32 kronor compared to 2.83 kronor. A one-time cost of 2.10 billion Swedish kronor related to the winding down of the Russian operations has impacted the result for the quarter. Net sales increased by 3 percent to 57.45 billion Swedish kronor from 55.58 billion Swedish kronor. In local currencies, net sales decreased by 4 percent.

"The autumn collections have been well received and sales in September are up on the previous year, providing important proof that the H&M group is growing even when customers' purchasing power is decreasing," said Helena Helmersson, CEO.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT